Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
229 USD +0.54% Intraday chart for Charles River Laboratories International, Inc. +0.99% -3.12%
Apr. 25 FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
Apr. 24 Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,416 12,366 18,969 11,086 12,127 11,761 - -
Enterprise Value (EV) 1 9,066 14,117 21,394 13,564 14,497 13,745 13,274 12,803
P/E ratio 29.9 x 34.5 x 49.5 x 23 x 25.6 x 28.3 x 23 x 19 x
Yield - - - - - - - -
Capitalization / Revenue 2.83 x 4.23 x 5.36 x 2.79 x 2.94 x 2.78 x 2.59 x 2.39 x
EV / Revenue 3.46 x 4.83 x 6.04 x 3.41 x 3.51 x 3.25 x 2.92 x 2.61 x
EV / EBITDA 15 x 20.1 x 24.3 x 13.7 x 14.3 x 12.9 x 11.3 x 9.86 x
EV / FCF 26.6 x 37.1 x 40.2 x 46 x 39.7 x 30.2 x 23.3 x 19.8 x
FCF Yield 3.75% 2.69% 2.49% 2.17% 2.52% 3.31% 4.3% 5.06%
Price to Book 4.55 x 5.85 x 7.46 x 3.73 x 3.37 x 2.9 x 2.53 x 2.18 x
Nbr of stocks (in thousands) 48,839 49,743 50,464 50,879 51,297 51,350 - -
Reference price 2 151.8 248.6 375.9 217.9 236.4 229.0 229.0 229.0
Announcement Date 2/11/20 2/17/21 2/16/22 2/22/23 2/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,621 2,924 3,540 3,976 4,129 4,223 4,544 4,912
EBITDA 1 604.4 701.3 879.5 990.9 1,013 1,063 1,176 1,298
EBIT 1 497.2 585 742.1 834 838.8 876.8 978.2 1,086
Operating Margin 18.97% 20.01% 20.96% 20.97% 20.31% 20.76% 21.53% 22.12%
Earnings before Tax (EBT) 1 304.1 447.1 480.7 623 581.3 552.4 692.7 821.5
Net income 1 252 364.3 391 486.2 474.6 419.7 525.1 629
Net margin 9.61% 12.46% 11.04% 12.23% 11.49% 9.94% 11.56% 12.8%
EPS 2 5.070 7.200 7.600 9.480 9.220 8.103 9.950 12.07
Free Cash Flow 1 340.4 380 532 294.9 365.4 455.3 570.8 647.8
FCF margin 12.99% 13% 15.03% 7.42% 8.85% 10.78% 12.56% 13.19%
FCF Conversion (EBITDA) 56.32% 54.19% 60.5% 29.76% 36.06% 42.84% 48.54% 49.91%
FCF Conversion (Net income) 135.08% 104.31% 136.07% 60.65% 76.98% 108.47% 108.7% 102.99%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/11/20 2/17/21 2/16/22 2/22/23 2/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 895.9 905 913.9 973.1 989.2 1,100 1,029 1,060 1,027 1,013 993.5 1,042 1,075 1,113 1,069
EBITDA 1 226.3 226.9 233.2 250.4 240.4 266.9 259.8 259.5 255.4 238.5 222.1 257.7 283.2 300.2 245
EBIT 1 191.8 189.1 196 211.7 201.4 224.8 217.8 216.2 210.9 193.9 177.8 212.3 236.5 250.7 203.3
Operating Margin 21.41% 20.89% 21.45% 21.75% 20.36% 20.44% 21.16% 20.4% 20.54% 19.14% 17.89% 20.37% 21.99% 22.52% 19.03%
Earnings before Tax (EBT) 1 123.3 163.6 110.8 144.1 123.1 244.9 131 128.7 112.9 208.7 96.3 130.2 156.9 172.8 145.2
Net income 1 103.4 137.6 93.02 109.3 96.47 187.4 103.1 97.02 87.39 187.1 71.21 99.9 119.8 131.8 102.8
Net margin 11.54% 15.2% 10.18% 11.23% 9.75% 17.04% 10.02% 9.15% 8.51% 18.46% 7.17% 9.58% 11.14% 11.84% 9.62%
EPS 2 2.010 2.670 1.810 2.130 1.880 3.650 2.010 1.890 1.690 3.620 1.350 1.918 2.305 2.522 1.960
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/3/21 2/16/22 5/4/22 8/3/22 11/2/22 2/22/23 5/11/23 8/9/23 11/8/23 2/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,650 1,751 2,425 2,477 2,370 1,985 1,513 1,042
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.73 x 2.497 x 2.758 x 2.5 x 2.339 x 1.867 x 1.287 x 0.8032 x
Free Cash Flow 1 340 380 532 295 365 455 571 648
ROE (net income / shareholders' equity) 22.7% 22% 22.8% 20.7% 16.7% 14.9% 14.6% 13.9%
ROA (Net income/ Total Assets) 7.82% 8.08% 8.48% 7.8% 6.95% 7.34% 8.04% 8.61%
Assets 1 3,222 4,508 4,612 6,232 6,830 5,716 6,533 7,303
Book Value Per Share 2 33.40 42.50 50.40 58.40 70.10 78.90 90.70 105.0
Cash Flow per Share 2 9.680 10.80 15.10 12.10 13.30 14.50 16.50 18.40
Capex 1 141 167 229 325 319 309 328 344
Capex / Sales 5.36% 5.7% 6.46% 8.17% 7.71% 7.32% 7.21% 7%
Announcement Date 2/11/20 2/17/21 2/16/22 2/22/23 2/14/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Charles River Laboratories International, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
229 USD
Average target price
270.7 USD
Spread / Average Target
+18.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. Financials Charles River Laboratories International, Inc.